{
  "trial_id": "NCT01142232",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "diagnosis of multiple myeloma at any stage of disease",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "undergoing high dose chemotherapy and stem cell transplantation",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "ECOG performance status of </= 2 at study entry",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Laboratory test results within protocol-specified ranges",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "All previous therapy not associated with peripheral blood stem cell transplant, including radiation, hormonal therapy, and surgery, must have been discontinued 4 weeks prior to treatment in this study",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Able to take aspirin daily as prophylactic anticoagulation",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Subject must have the minimum stem cell dose of 5.0 x 10^6 CD34+ cells/kg collected",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Females of childbearing potential must have negative pregnancy test within 24 hours of first prescription for lenalidomide and must commit to either continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control",
      "label": "unknown",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Pregnant or breast feeding females",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "History of intolerance or resistance to lenalidomide",
      "label": "unknown",
      "evidence": "unknown"
    },
    {
      "criterion": "Known hypersensitivity to thalidomide",
      "label": "unknown",
      "evidence": "unknown"
    },
    {
      "criterion": "The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.",
      "label": "unknown",
      "evidence": "unknown"
    },
    {
      "criterion": "Known seropositive for or active viral infection with human immunodeficiency vrus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis b virus vaccine are eligible.",
      "label": "not_met",
      "evidence": "quote"
    }
  ],
  "notes": "Patient has multiple myeloma, s/p allogeneic transplant with recurrent disease and systemic amyloidosis. She is on hemodialysis for ESRD and represents for malaise, weakness, and generalized body aching x 2 days.",
  "_meta": {
    "topic_id": "17",
    "trial_id": "NCT01142232",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}